Core Viewpoint - Sinovac's seasonal flu vaccine has received official registration from the Ministry of Health and Prevention of the United Arab Emirates, marking a significant milestone for the company in expanding its vaccine portfolio and market reach [1]. Group 1: Company Developments - Sinovac's seasonal flu vaccine is now officially registered in the UAE, enhancing its credibility and market presence in the region [1]. - The vaccine has been widely used in over 20 countries and regions globally, indicating strong international demand and acceptance [1]. Group 2: Market Impact - The cumulative supply of Sinovac's seasonal flu vaccine has exceeded 120 million doses, showcasing the company's production capacity and distribution effectiveness [1].

Core Insights - The Chilean government has awarded Beijing Sinovac Biotech Co., Ltd. (Sinovac) the exclusive supply contract for the 2026 flu vaccine, with over 8 million doses ordered [1] - This marks the second consecutive year that Sinovac has been the sole supplier for Chile's flu vaccine, indicating the company's product quality and international compliance capabilities are recognized by the Chilean public health system [1] - In 2025, Sinovac supplied over 8.3 million doses of flu vaccine in Chile, achieving an approximately 80% vaccination rate among the target population, which laid a solid foundation for the renewal of the contract [1] Collaboration and Research - Sinovac's collaboration with various partners in Chile has expanded from product supply to research cooperation and evidence building [2] - A multi-center clinical study on the quadrivalent flu vaccine, co-conducted by Sinovac and research partners from Chile and other countries, was published in the journal "Vaccines," confirming the vaccine's good immunogenicity and safety [2] - Another Phase III study evaluating both humoral and cellular immune responses in Chilean adults was published in "Nature Communications," further demonstrating the scientific basis for the good immunogenicity and safety of Sinovac's flu vaccine [2] Global Expansion - Sinovac's flu vaccine has been applied globally, entering nearly 20 countries and regions, with a cumulative supply of over 120 million doses, contributing to global flu prevention efforts [2]

Core Insights - The Chilean government announced the results of the 2026 global tender for flu vaccines, with Sinovac becoming the exclusive supplier, securing orders exceeding 8 million doses [1] - This marks the second consecutive year that Sinovac has been the sole supplier for Chile's flu vaccine needs, indicating the recognition of Sinovac's product quality and international fulfillment capabilities by the country's public health system [1] - In 2025, Sinovac's flu vaccines administered in Chile exceeded 8.3 million doses, achieving approximately 80% coverage of the target population, which laid a solid foundation for the renewal of the contract [1] Group 1 - The first batch of vaccines is expected to arrive in Chile by the end of January 2026, meeting the country's flu season protection needs [1] - Sinovac's collaboration with various partners in Chile has expanded from product supply to research collaboration and evidence building [1] - A multi-center clinical study on the quadrivalent flu vaccine, co-conducted by Sinovac and research partners from Chile and other countries, was published in the journal "Vaccines," confirming the vaccine's good immunogenicity and safety [1] Group 2 - Sinovac's flu vaccine has shown higher antibody titers against four types of influenza viruses compared to foreign control vaccines [1] - A Phase III study evaluating both humoral and cellular immune responses in the adult population in Chile was published in "Nature Communications," further demonstrating the scientific basis for the vaccine's good immunogenicity and safety [1] - Sinovac's flu vaccine continues to expand its global application, having entered nearly 20 countries and regions, with a cumulative supply of over 120 million doses, providing stable support for global flu prevention [2]

Group 1 - The Shanghai Cooperation Organization (SCO) held its eighth health ministers' meeting in Xi'an, focusing on promoting sustainable health development and sharing a healthy future [1] - SCO member countries agreed to deepen cooperation in emergency medicine, primary health care, digital health, and traditional medicine [1] - Chinese vaccine company Sinovac has established a diverse cooperation system with multiple countries under the SCO framework, covering research, supply, and industrialization [1] Group 2 - Sinovac has supplied over 33 million doses of routine vaccines, including hepatitis A, flu, and varicella vaccines, to SCO member countries [1] - The hepatitis A vaccine from Sinovac is the preferred choice for immunization programs in several SCO countries, with over 10 million doses supplied to Uzbekistan, Kazakhstan, India, and Pakistan [1] - In Uzbekistan, Sinovac's hepatitis A vaccine achieved over 95% market share in the private sector, with a coverage rate exceeding 69% for children in 2024 [1] Group 3 - Sinovac's varicella vaccine received prequalification from the World Health Organization, and it was first supplied to Belarus in late 2023, addressing a shortage of varicella vaccines [1] - Sinovac's flu vaccine was launched in Pakistan in 2024 and quickly became a mainstream brand [2] - Sinovac donated 100,000 doses of inactivated hepatitis A vaccine to Pakistan during severe flooding in 2022, receiving appreciation from local health authorities [2] Group 4 - Sinovac is actively engaged in industrial cooperation with SCO partners, including establishing a vaccine factory in Turkey and building a large automated vaccine cold storage facility in Egypt [2] - The cold storage facility in Egypt is the largest vaccine storage center in Africa, covering an area of 2,800 square meters [2] - Sinovac has developed 12 vaccines over its 24 years of operation, gaining wide recognition globally [2]